| Literature DB >> 32162081 |
Wei Li1, Huaqian Cui2, Kunwei Li1, Yijie Fang1, Shaolin Li3.
Abstract
BACKGROUND: Infection with COVID-19 is currently rare in children.Entities:
Keywords: COVID-19; Child; Computed tomography; Coronavirus; Pneumonia; Viral
Mesh:
Year: 2020 PMID: 32162081 PMCID: PMC7080075 DOI: 10.1007/s00247-020-04656-7
Source DB: PubMed Journal: Pediatr Radiol ISSN: 0301-0449
Fig. 1Axial non-enhanced chest CT in a boy age 1 year 5 months (Patient 1 in Table 1). a Four days after admission there is patchy ground-glass opacification (arrowheads) of the right upper lobe. b Five days subsequently, during antiviral treatment, the appearances have normalised
Fig. 2Axial non-enhanced chest CT in a 4-year-old boy (Patient 4 in Table 1). a Two days after admission there is patchy ground-glass opacification (arrowheads) of the left lower lobe. b Five days subsequently, during symptomatic and supportive treatment, the appearances have normalised
Fig. 3Axial non-enhanced chest CT in a 3-year-old boy (Patient 3 in Table 1). a Nine days after onset of symptoms, there is patchy ground-glass opacification (arrowheads) in the left lower lobe. b Seven days subsequently, during antiviral treatment, the appearances have normalised
Patient demographics, treatment and outcomes
| Patient | Age/gender | Presenting history | RT-PCR positive | CRP at presentation, mg/L | White blood cells, ×109/L | Initial chest CT | Treatment | Follow-up chest CT | Length of hospital stay | Outcomea | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days from admission or onset of symptoms to scan | Findings | Days after initial CT | Findings | |||||||||
| 1 | 1 y 5 m/M | Asymptomatic, grandmother positive RT-PCR | 6th test | 9.4 | 9.2 | 4 | Patchy ground-glass opacities | Antiviral, anti-infective therapy, immunoglobulin therapy, interferon, Lianhua qingwen granules | 5 | Normal | Remains in hospital for observation; 24 days at time of writing | |
| 2 | 10 m/F | Asymptomatic, parents and grandparents positive RT-PCR | 1st test | 0.9 | 14.8 | 2 | Normal | Montelukast sodium chewable tablets, immunoglobulin therapy | Not performed | 14 days | Discharged home | |
| 3 | 3 y/M | Runny nose, cough, sputum, sore throat, fever after 3 days; father positive RT-PCR | 1st test | 0.7 | 15.0 | 9 | Patchy ground- glass opacities | Antiviral, anti-infective therapy, immunoglobulin therapy | 7 | Normal | 12 days | Discharged home |
| 4 | 4 y/M | Asymptomatic, father positive RT-PCR | 1st test | 0.2 | 6.6 | 2 | Patchy ground- glass opacities | Montelukast sodium chewable tablets, immunoglobulin therapy | 5 | Normal | 13 days | Discharged home |
| 5 | 6 y/M | Asymptomatic, travelled from high-endemic area (Wuhan) | 1st test | 0.6 | 5.3 | 3 | Normal | Interferon, Montelukast sodium chewable tablets, immunoglobulin therapy | Not performed | Remains in hospital for observation; 13 days at time of writing | ||
CRP C-reactive protein, CT computed tomography, F female, M male, m months, RT-PCR reverse transcriptase polymerase chain reaction test for COVID-19, y years
aRecovery defined as afebrile, improved respiratory symptoms, normalised chest CT, and two consecutive (24-h interval) RT-PCR tests negative